Avastin
(Bevacizumab)ApprovedMonoclonal antibody
Bevacizumab is used to treat certain cancers by blocking the growth of new blood vessels that feed tumors, which helps stop cancer cells from growing and spreading.[2] Avastin is currently approved and in use across 269 indications[4].[1]
Avastin is one of 2771 biologic programs targeting Glioma. It is currently in Approved.
269
Indications
2,008
Total Trials
35
Active Trials
2,770
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 268 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Avastin
BBio-Thera Solutions
Approved
Trodelvy
GileadPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Prolia
AmgenPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer18 trials
Show 15 more trials
Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer
Not yet recruiting·—·Phase 2·NCT07286695·292 enrolled
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
Active, not recruiting·
Institut de Recherches Internationales Servier·Phase 3·NCT03869892·856 enrolled
Institut de Recherches Internationales Servier·Phase 3·NCT03869892·856 enrolledA Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
Unknown status·—·Phase 3·NCT04188145·400 enrolled
Breast Cancer17 trials
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
Unknown status·—·Phase 2·NCT00378638·30 enrolled
Show 14 more trials
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Completed·—·Phase 2·NCT00472693·5 enrolled
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Unknown status·—·Phase 2·NCT04389073·138 enrolled
Bevacizumab17 trials
Show 14 more trials
Treatment of Bevacizumab Followed by Steroid in RN
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04553510·86 enrolled
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Completed·—·Phase 2·NCT00612430·59 enrolled
Colorectal Cancer16 trials
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07007767·32 enrolled
Show 13 more trials
Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT05364489·20 enrolled
Hepatocellular Carcinoma10 trials
Show 7 more trials
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05617430·43 enrolled
79 more indications
Non-Small Cell Lung Cancer7 trials
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05507606·50 enrolled
Show 4 more trials
Ovarian Cancer5 trials
Age-Related Macular Degeneration4 trials
Glioma4 trials
A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
Completed·—·Phase 2·NCT00921167·32 enrolled
Show 1 more trial
Glioblastoma4 trials
Amgen 386 for Recurrent Glioblastoma
Completed·—·Phase 1/2·NCT01290263·48 enrolled
Show 1 more trial
Malignant Glioma4 trials
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Completed·—·Phase 2·NCT00671970·57 enrolled
Show 1 more trial
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Active, not recruiting·—··NCT07448480·1,000 enrolled
Prostate Cancer3 trials
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
Completed·—·Phase 2·NCT00349557·18 enrolled
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
Completed·—·Phase 2·NCT00321646·42 enrolled
Glioblastoma Multiforme3 trials
Neuroendocrine Tumors2 trials
Visual Impairment2 trials
Rectal Cancer2 trials
DCE-MRI PET Bevacizumab Study in Rectal Cancer
Withdrawn·—·Phase 2·NCT01426074
Lung Cancer2 trials
Colorectal Adenocarcinoma2 trials
Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.
Unknown status·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT01067053·69 enrolled
Retinopathy of Prematurity2 trials
Pleural effusion2 trials
Advanced Solid Tumors2 trials
Renal Cell Carcinoma2 trials
Capecitabine2 trials
Efficacy and Safety2 trials
Chemotherapy2 trials
Fluorescence2 trials
Colorectal Carcinoma2 trials
Non-squamous NSCLC2 trials
Macular Degeneration2 trials
Diabetic Macular Edema2 trials
Choriocarcinoma1 trial
Mesothelioma1 trial
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Completed·—·Phase 2·NCT00137826·37 enrolled
Mucosal Melanoma1 trial
Neoadjuvant Treatment1 trial
Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer
Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT01043484·90 enrolled
Macular Edema1 trial
Locally-advanced Rectal Cancer1 trial
Familial adenomatous polyposis1 trial
Endometriosis1 trial
Liver Transplant1 trial
Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05355155·15 enrolled
Pilot Study1 trial
Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis
Completed·—·Phase 1/2·NCT00891527·50 enrolled
Melanoma1 trial
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Completed·—·Phase 1·NCT00790010·46 enrolled
Malignant Pleural Mesothelioma1 trial
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Completed·—·Phase 2·NCT00407459·77 enrolled
Soft-tissue Sarcomas1 trial
Cancer of the Esophagus1 trial
Synovitis1 trial
Anaplastic Astrocytoma1 trial
Safety and Efficacy1 trial
Carboplatin1 trial
Nasopharyngeal Carcinoma1 trial
Primary Peritoneal1 trial
Ovarian Clear Cell Carcinoma1 trial
Neuroblastoma1 trial
Randomized1 trial
Blood Pressure Monitoring1 trial
Newly Diagnosed1 trial
Pancreatic Cancer1 trial
First-line Treatment1 trial
Renal Cell Cancer1 trial
Treatment Failure1 trial
Pterygium1 trial
Topical Bevacizumab for Preventing Recurrent Pterygium
Completed·—·Phase 3·NCT01311960·24 enrolled
Unresectable1 trial
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05029973·30 enrolled
Treatment1 trial
Thyroid Cancer1 trial
Second-line Treatment1 trial
Leptomeningeal Metastasis1 trial
Leukemia1 trial
Neoadjuvant Chemotherapy1 trial
Proliferative Diabetic Retinopathy1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Feb 26, 2004
Avastin
BLA 125085
Feb 26, 2004
AVASTIN
BLA BLA125085
Dec 6, 2023
AVZIVI TNJN
BLA BLA761198
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Avastin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Vascular Endothelial Growth Factor a Inhibitor[3]
- Modality
- Monoclonal antibody[3]
- Highest Phase
- Approved[1]
- Company
- BBio-Thera Solutions